Medartis Holding Ag · SIX:MED
Medartis — H1 2026 Earnings Presentation
34 slides from Medartis's earnings presentation, Aug 18, 2026
Slide 1: 2026 | Half-year results
2026 | Half-year results Matthias Schupp, CEO | Peter Hackel, CFO Basel, 18 August 2026
Slide 2: Disclaimer
Disclaimer This communication does not constitute an offer or invitation to subscribe for or purchase any securities of Medartis Holding AG. This publication may contain certain forward-looking statements and assessments or intentions concerning the company and its business. Such statements involve
Slide 3: H1 2026 | Delivering on our promises
H1 2026 | Delivering on our promises ⎼ We are ON TRACK: Organic sales in H1 rose 17.0% and the core EBITDA margin increased to 18.0% ⎼ TOUCH ROLLOUT in the US and Australia now fully under way ⎼ FESSH Congress in Basel and 2nd TOUCH congress showed RECORD ATTENDANCE ⎼ NeoOrthos 'Cold Fusion' project
Slide 4: Key highlights │ Keeping our promises
Key highlights │ Keeping our promises CHF Group Organic revenue EBITDA 2026 revenue growth1 margin Guidance 160.8million 17.0% CER 18.0% core 2 RAISED − Up 30.7% including − Driven by dynamic − +0.2pp (CHF) or − Based on business contributions of growth in the US and +0.9pp (CER) performance to date
Slide 5: US and EMEA outpacing
US and EMEA outpacing 27,4% 17,7% US EMEA 9,6% LATAM 5,5% APAC 17,0% Worldwide 5
Slide 6: Financial review
Financial review Peter Hackel, CFO
Slide 7: US and EMEA were the key growth contributors in H1
US and EMEA were the key growth contributors in H1 Core sales1 in million CHF and yoy growth rates Organic 17,0% 0.9 1.5 160.2 6.5 14.3 18.6 137.0 122.1 -3.7 17,7% 27,4% 5,4% 9,6% Core sales FX M&A sales Adj. core sales EMEA US APAC LATAM Core sales H1 2025 impact H1 2025 CER H1 2026 7 1 Core growth
Slide 8: Upper extremities driven by H&W portfolio
Upper extremities driven by H&W portfolio Breakdown by category (left) and organic growth in H1 2026 in % (right) − Largest segment UE with dynamic growth Lower CMF & driven by strong sales in H&W, high trauma extremities Others 21.1 volumes in Europe due to severe winter 16% 13% conditions and expa
Slide 9: US tariffs impact | Mitigation strategy in place
US tariffs impact | Mitigation strategy in place ⎼ The core result includes a tariff charge of CHF 0.9 million related to implants sold in H1 2026 (representing an approx. tariff rate of 12.5%) ⎼ In H1 2025 we had no substantial US tariff expenses ⎼ For part of 2025, US tariffs on implants sold were
Slide 10: Reconciliation of APMs in H1 2026
Reconciliation of APMs in H1 2026 − M&A effects: The amortisation of intangible non-core IFRS 2026.6 M&A effects Other CORE 2026.6 CORE 2025.6 (in CHF thousands) business Net revenue 160’835 - (638) - 160’198 122’050 assets of CHF 1.0 million related to historical Cost of goods sold (29’433) 16 1’48
Slide 11: Gross margin | Margin +1.4pp on Keri Medical integration
Gross margin | Margin +1.4pp on Keri Medical integration and stronger Medartis margin in % of net sales, rounded − Gross margin impacted +1.4pp by FX and new US tariffs (0.6pp and 0.6pp) 0.5 0.7 81.5 0.2 81.7 − M&A consolidation -0.6 effect had a net impact 0.7 of 0.5pp incl. 1.2 80.1 internalisatio
Slide 12: EBITDA | Core profitability increased thanks to OPEX leverage
EBITDA | Core profitability increased thanks to OPEX leverage in % of net sales, rounded +0.9 PP 0.4 -0.9 − Core EBITDA margin 1.4 increased +0.9 PP at 18.0 -0.9 CER − Investment in growth 0.8 17.1 17.2 17.0 -0.7 initiatives while keeping overall cost discipline − NeoOrtho with positive effect on EB
Slide 13: Net result | Bottom-line driven by improved result and FX gains
Net result | Bottom-line driven by improved result and FX gains In CHF million +7.2 − Improved finance result of 6.7 -3.6 CHF 6.7 million; mainly attributable to FX despite higher interest expense and 6.8 -1.9 finance transaction fees of 5.3 -1.0 4.9 CHF 1.3 million -0.2 − Tax expense +CHF 3.6 milli
Slide 14: Free cashflow | FCF at CHF million due to increased CAPEX
Free cashflow | FCF at CHF 9 million due to increased CAPEX investments In CHF million 7.8 -17.9 − CAPEX increased due to capacity investments (building and machinery) in various sites 33.0 − NWC: CHF 4.1 million higher inventory for new surgical sets 17.3 0.3 25.8 (inventory) and -14.7 CHF 4.4 mill
Slide 15: Strategy update
Strategy update Matthias Schupp, CEO 15
Slide 16: Strategic priorities: Unchanged
Strategic priorities: Unchanged CUSTOMERS AT THE CENTRE OF WHAT WE DO Accelerate Keri Medical Value Regional Innovation & Improve US Strategy share gains Digitalisation Cashflow HIGH PERFORMANCE CULTURE with a high-performance team 16 16
Slide 17: Firmly on track to meet our full-year TOUCH projection
Firmly on track to meet our full-year TOUCH projection Annual TOUCH volumes (in thousands of units) − Keri Medical continued to grow dynamically. Sales surged by 45% in Medartis's direct-distribution countries (e.g. Austria, Germany and the UK) and by 30% in 60 the business with external distributio
Slide 18: Medartis Group with strong presence at CMC1 and FESSH congresses
Medartis Group with strong presence at CMC1 (Nice) and FESSH congresses (Basel) 18
Slide 19: ONE TEAM
ONE TEAM CEO Executive Management Board MATTHIAS SCHUPP as of 1 January 2027 CEO Matthias Schupp KeriMedical Advisory Board Assistant CEO – Board Secretary CEO Assistant – Board Secretary ANTONIETTA FASOLIN DOUGAL BENDJABALLAH & BERNARD PRANDI Antonietta Fasolin COO CFO and US a.i. GM Keri Medical C
Slide 20: Julie Mottet from Keri Medical to join the EMB
Julie Mottet from Keri Medical to join the EMB ⎼ Given its strategic relevance for our Group, we have decided that Keri Medical will be represented on the EMB on 1 January 2027 ⎼ Julie Mottet will join the Group EMB, having previously been a member of our EMG ⎼ Keri Medical's operations are scaling
Slide 21: We are expanding capacity in all our sites
We are expanding capacity in all our sites Complex personalised implants; Gent, Belgium Instruments & implants Keri Medical, Besançon, France Premium Implants & Instrument-Production Warsaw, US HQ /premium implant Implants; KeriMedical, production; Archamps, France Basel, Switzerland Value Implants
Slide 22: Keri Medical | Opening of Archamps expansion
Keri Medical l Opening of Archamps expansion Slider animation 22
Slide 23: New production facility in Besançon due to open in H1 2028
New production facility in Besançon due to open in H1 2028
Slide 24: New NeoOrtho facility officially opened
New NeoOrtho facility officially opened 24
Slide 25: New NeoOrtho facility officially opened
New NeoOrtho facility officially opened 25
Slide 26: Outlook 2026
medartis group Outlook 2026
Slide 27: New 'Titan Nail' launched in August
New ‘Titan Nail’ launched in August l excellent feedback from American surgeons right from the start ⎼ ‘Titan Nail’ is an intramedullary implant that stabilises the bone from within rather than through a plate-and-screw construct ⎼ Designed to reduce soft-tissue exposure and operating time in suitab
Slide 28: The new Proximal Humerus system in limited release
The new Proximal Humerus system in limited release − Addressing a top-3 indication where we are not present today − New PentaLock locking system for selected indications to compliment the APTUS portfolio − Anatomical plated design to fit individual bone and soft tissue conditions feat. spiral blade
Slide 29: New Outlook 2026
New Outlook 2026 (barring any unforeseen circumstances) ORGANIC1 GROWTH CORE EBITDA MARGIN 17 - 19% in the high teens Core Sales at CER 1 Organic growth denotes the increase in sales at constant exchange rates (CER), excluding the sales from acquired or sold businesses (i.e. NeoOrtho, KeriMedical, C
Slide 30: Accelerating momentum
Accelerating momentum Organic 17-19% 269,3 CHF +13% Organic +14% 224,8 212,0 182,8 Net sales (in CHF million) 159,9 Core EBITDA-Margin (in %) 130,1 127,6 High Pandemic 18.4% teens 15.3% 2019 2020 2021 2022 2023 2024 2025 E2026 30
Slide 31: medartis group
medartis group 31
Slide 32: Upcoming corporate events
Upcoming corporate events Date Event Destination Broker Broadcasting 18 August 2026 half-year results publication Online Yes 01 September Reverse roadshow Basel Octavian 02 September Non-deal roadshow Geneva ZKB 03 September Non-deal roadshow Paris Octavian 22 September Non-deal roadshow London ZKB
Slide 33: Analyst coverage: For independent research opinions
Analyst coverage: For independent research opinions Broker Analyst Email Telephone Octavian Sandra Dietschy sandra.dietschy@octavian.ch +41 44 518 08 27 Research Partners AG Eugen Perger eugen.perger@researchpartners.ch +41 44 533 40 30 Stifel Nicolaus Europe Ltd. Edward Hall ed.hall@stifel.com +44
Slide 34: THANK YOU!
THANK YOU! info@medartis.com +41 61 633 37 36 Hochbergerstrasse 60E 4057 Basel/Switzerland M E D A R T I S . C O M 34